Next 10 |
home / stock / nwphf / nwphf news
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year Presentation of study design for potentially pivotal phase III trial for TRS patients Information on potentially pivotal st...
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...
Ad hoc announcement pursuant to Art. 53 LR Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically important reducti...
Ad hoc announcement pursuant to Art. 53 LR 290 patients participate at study centers in Europe, Asia and Latin America Results from the study are expected in March 2024 Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutica...
Ad hoc announcement pursuant to Art. 53 LR 40% of patients no longer met TRS severity criteria Company presented data from study in treatment resistant schizophrenia (TRS) confirming therapeutic durability and efficacy at the 36 th ECNP Congress in Barcelona Data after...
Poster presentations will include the full results from all 161 patients randomized in study 014 at the six-month time point from extension study 015, a Phase II trial evaluating evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS) The company will also...
2023-08-04 12:45:15 ET Newron Pharmaceuticals press release ( OTC:NWPHF ): 1H GAAP EPS of -€0.39. Q2 Licence income/Royalties/Other income of €5.50M vs €2.83M a year ago. For further details see: Newron Pharmaceuticals GAAP EPS of -€0.39
Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced i...
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data from first 100 patients at the one-year interim timepoint confirm significant and clinically important, sustained and gradually increasing efficacy ...
Further data from study 014/015 of evenamide in treatment-resistant schizophrenia (TRS) confirms potentially relevant role of glutamatergic release modification when added to TRS patients not responding to marketed antipsychotics International TRS advisory committee will contribute to des...
News, Short Squeeze, Breakout and More Instantly...
Newron Pharms Spa Ord Company Name:
NWPHF Stock Symbol:
OTCMKTS Market:
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year Presentation of study design for potentially pivotal phase III trial for TRS patients Information on potentially pivotal st...
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...
Ad hoc announcement pursuant to Art. 53 LR Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically important reducti...